{"data":{"id":"us-ca/hsc-11839.2","jurisdiction":"us-ca","citation":"HSC § 11839.2","heading":"","body":"The following medications are authorized for use in narcotic replacement therapy and medication-assisted treatment by licensed narcotic treatment programs:\n(a) Methadone.\n(b) Buprenorphine products or combination of products approved by the federal Food and Drug Administration for treatment of opioid dependence.\n(c) Any other medication approved by the federal Food and Drug Administration for the purpose of narcotic replacement treatment or medication-assisted treatment of substance use disorders.\n(d) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of plan or provider bulletins, or similar instructions. The department shall adopt regulations by no later than January 1, 2021.","path":["Health and Safety Code - HSC","DIVISION 10.5. ALCOHOL AND OTHER DRUG PROGRAMS [11750. - 11975.]","PART 2. STATE GOVERNMENT'S ROLE TO ALLEVIATE PROBLEMS RELATED TO THE INAPPROPRIATE USE OF ALCOHOLIC BEVERAGES AND OTHER DRUG USE [11760. - 11872.]","CHAPTER 10. Narcotic Treatment Programs [11839. - 11839.34.]","ARTICLE 1. Narcotic Treatment Programs [11839. - 11839.22.]"],"source_url":"https://downloads.leginfo.legislature.ca.gov/pubinfo_2025.zip","current_through":"2026-09-13","vintage":"","retrieved_at":"2026-09-14T05:56:33Z","sha256":"c236bbedddbc02c4fe8684184178bf7a55fc4174e3cdba2b8e1880cc5d3ba2bf","source_id":"us-ca","stale":false,"prev":"us-ca/hsc-11839.1","next":"us-ca/hsc-11839.3"},"notice":"GroundRules: Original legal text. Not legal advice."}